VistaGen Therapeutics Inc./$VTGN
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About VistaGen Therapeutics Inc.
Vistagen Therapeutics Inc is a late clinical-stage therapeutics company focused on developing and commercializing medicines for patients with social anxiety disorder, depression, menopausal hot flashes, psychomotor impairment due to mental fatigue, and cancer cachexia. The company is engaged in developing intranasal product candidates called pherines, which leverage the understanding of nose-to-brain neurocircuitry. Vistagen's pherine pipeline consists of various product candidates like: Fasedienol, Itruvone, PH15, Refisolone, and PH284, which are being developed to provide treatment for a variety of disorders. Additionally, it is seeking potential partners for the further clinical development and commercialization of an oral drug candidate, AV-101, to treat certain neurological disorders.
Ticker
$VTGN
Sector
Primary listing
Employees
41
Headquarters
Website
VTGN Metrics
BasicAdvanced
$9.9m
-
-$1.83
0.29
-
Price and volume
Market cap
$9.9m
Beta
0.29
52-week high
$5.14
52-week low
$0.20
Average daily volume
3.2m
Financial strength
Current ratio
3.669
Quick ratio
3.548
Long term debt to equity
0.701
Total debt to equity
2.939
Profitability
EBITDA (TTM)
-71.927
Gross margin (TTM)
100.00%
Net profit margin (TTM)
-5,491.33%
Operating margin (TTM)
-5,683.69%
Effective tax rate (TTM)
-0.01%
Revenue per employee (TTM)
$30,000
Management effectiveness
Return on assets (TTM)
-67.84%
Return on equity (TTM)
-131.59%
Valuation
Price to revenue (TTM)
7.231
Price to book
0.27
Price to tangible book (TTM)
0.27
Price to free cash flow (TTM)
-0.138
Free cash flow yield (TTM)
-725.69%
Free cash flow per share (TTM)
-1.749
Growth
Revenue change (TTM)
161.11%
Earnings per share change (TTM)
9.91%
3-year revenue growth (CAGR)
77.48%
3-year earnings per share growth (CAGR)
-40.10%
10-year earnings per share growth (CAGR)
-46.03%
VTGN News
AllArticlesVideos
Penny Stock Vistagen Keeps Regulatory Plans Alive Despite Anxiety Study Miss
Benzinga·1 month ago
Vistagen Reports Fiscal Year 2026 Financial Results and Provides Corporate Update
Business Wire·2 months ago
Vistagen Announces Preliminary Positive Data in Ongoing Open-Label Extension Portion of PALISADE-3 Phase 3 Study of Fasedienol for the Acute Treatment of Social Anxiety Disorder
Business Wire·3 months ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.